|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
Journal of Cell Science, Vol 113, Issue 13 2445-2453, Copyright © 2000 by Company of Biologists
JOURNAL ARTICLES |
K Fuller, JM Lean, KE Bayley, MR Wani and TJ Chambers
Department of Histopathology, St George's Hospital Medical School, London SW17 0RE, UK. k.fuller@sghms.ac.uk
Recently, tumour necrosis factor-related activation-induced cytokine (TRANCE) was shown to be necessary for osteoclast formation. We now report that TGF(beta), a cytokine enriched in bone matrix, is also required. TGF(beta) not only powerfully synergized with TRANCE for induction of osteoclast-like cells (OCL) from bone marrow precursors and monocytes, but OCL formation was abolished by recombinant soluble TGF(beta) receptor II (TGF(beta)sRII). Preincubation in TGF(beta) was as effective as simultaneous incubation with TRANCE. TGF(beta)-preincubation enhanced OCL formation at least partly by preventing the development of resistance to OCL-induction that otherwise occurs when precursors are incubated in M-CSF. OCL formed in TRANCE also showed more rapid apoptosis than OCL in TRANCE plus TGF(beta). Like TGF(beta), incubation on bone matrix prolonged and enhanced the sensitivity of precursors to OCL-induction by TRANCE, and this was reversed by TGF(beta)sRII. Taken together, this data is compelling evidence for a model in which TGF(beta) in matrix or released from bone-lining or other cells maintains and enhances the osteoclast-forming potential of precursors as they migrate towards sites of cell-bound TRANCE. Thus, the specific circumstances necessary for osteoclast formation and survival are TRANCE expression on osteoblastic cells and TGF(beta) in bone.
This article has been cited by other articles:
|
|
 |
|
  X. Tan, T. Weng, J. Zhang, J. Wang, W. Li, H. Wan, Y. Lan, X. Cheng, N. Hou, H. Liu, et al. Smad4 is required for maintaining normal murine postnatal bone homeostasis J. Cell Sci., July 1, 2007; 120(13): 2162 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mochizuki, M. Takami, T. Kawawa, R. Suzumoto, T. Sasaki, A. Shiba, H. Tsukasaki, B. Zhao, R. Yasuhara, T. Suzawa, et al. Identification and Characterization of the Precursors Committed to Osteoclasts Induced by TNF-Related Activation-Induced Cytokine/Receptor Activator of NF-{kappa}B Ligand J. Immunol., October 1, 2006; 177(7): 4360 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul Transforming Growth Factor-{beta}1 to the Bone Endocr. Rev., October 1, 2005; 26(6): 743 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kim, Y. Kadono, M. Takami, J. Lee, S.-H. Lee, F. Okada, J. H. Kim, T. Kobayashi, P. R. Odgren, H. Nakano, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis J. Exp. Med., September 6, 2005; 202(5): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Mangashetti, S. M. Khapli, and M. R. Wani IL-4 Inhibits Bone-Resorbing Activity of Mature Osteoclasts by Affecting NF-{kappa}B and Ca2+ Signaling J. Immunol., July 15, 2005; 175(2): 917 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Yogesha, S. M. Khapli, and M. R. Wani Interleukin-3 and Granulocyte-Macrophage Colony-stimulating Factor Inhibits Tumor Necrosis Factor (TNF)-{alpha}-induced Osteoclast Differentiation by Down-regulation of Expression of TNF Receptors 1 and 2 J. Biol. Chem., March 25, 2005; 280(12): 11759 - 11769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wang, H. Yamamoto, J. R. Chin, Z. Werb, and T. H. Vu Epidermal Growth Factor Receptor-deficient Mice Have Delayed Primary Endochondral Ossification Because of Defective Osteoclast Recruitment J. Biol. Chem., December 17, 2004; 279(51): 53848 - 53856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kenner, A. Hoebertz, T. Beil, N. Keon, F. Karreth, R. Eferl, H. Scheuch, A. Szremska, M. Amling, M. Schorpp-Kistner, et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects J. Cell Biol., February 16, 2004; 164(4): 613 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O'Gradaigh and J. E. Compston T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion Rheumatology, February 1, 2004; 43(2): 122 - 130. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Karsdal, P. Hjorth, K. Henriksen, T. Kirkegaard, K. L. Nielsen, H. Lou, J.-M. Delaisse, and N. T. Foged Transforming Growth Factor-{beta} Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression J. Biol. Chem., November 7, 2003; 278(45): 44975 - 44987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Novack, L. Yin, A. Hagen-Stapleton, R. D. Schreiber, D. V. Goeddel, F. P. Ross, and S. L. Teitelbaum The I{kappa}B Function of NF-{kappa}B2 p100 Controls Stimulated Osteoclastogenesis J. Exp. Med., September 2, 2003; 198(5): 771 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. A. McGowan, H. MacPherson, K. Janssens, W. Van Hul, J. C. Frith, W. D. Fraser, S. H. Ralston, and M. H. Helfrich A Mutation Affecting the Latency-Associated Peptide of TGF{beta}1 in Camurati-Engelmann Disease Enhances Osteoclast Formation in Vitro J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3321 - 3326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Khapli, L. S. Mangashetti, S. D. Yogesha, and M. R. Wani IL-3 Acts Directly on Osteoclast Precursors and Irreversibly Inhibits Receptor Activator of NF-{kappa}B Ligand-Induced Osteoclast Differentiation by Diverting the Cells to Macrophage Lineage J. Immunol., July 1, 2003; 171(1): 142 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Fox, S. J. Haque, A. C. Lovibond, and T. J. Chambers The Possible Role of TGF-{beta}-Induced Suppressors of Cytokine Signaling Expression in Osteoclast/Macrophage Lineage Commitment In Vitro J. Immunol., April 1, 2003; 170(7): 3679 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers TNF{alpha} Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL Endocrinology, March 1, 2002; 143(3): 1108 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kim, M. Takami, J. Rho, R. Josien, and Y. Choi A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation J. Exp. Med., January 14, 2002; 195(2): 201 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Itoh, N. Udagawa, T. Katagiri, S. Iemura, N. Ueno, H. Yasuda, K. Higashio, J. M. W. Quinn, M. T. Gillespie, T. J. Martin, et al. Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-{kappa}B Ligand Endocrinology, August 1, 2001; 142(8): 3656 - 3662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert Omega-3 Polyunsaturated Fatty Acids and Skeletal Health Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. HOEBERTZ, S. MEGHJI, G. BURNSTOCK, and T. R. ARNETT Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y1 receptor on bone cells FASEB J, May 1, 2001; 15(7): 1139 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Fox, K. Fuller, K. E. Bayley, J. M. Lean, and T. J. Chambers TGF-{beta}1 and IFN-{gamma} Direct Macrophage Activation by TNF-{alpha} to Osteoclastic or Cytocidal Phenotype J. Immunol., November 1, 2000; 165(9): 4957 - 4963. [Abstract] [Full Text] [PDF]
|
|
